No clear choice between NOS and AXIS to assess methodological quality in cross-sectional studies of health-related quality-of-life and breast cancer

To compare the inter-rater reliability, concurrent validity, completion time, and ease of use of two methodological quality (MQ) assessment tools for cross-sectional studies: an adapted Newcastle-Ottawa Scale (NOS) and the Appraisal Tool for Cross-Sectional Studies (AXIS).
Source: Journal of Clinical Epidemiology - Category: Epidemiology Authors: Tags: Original Article Source Type: research

Related Links:

PURPOSE: Cross-sectional studies suggest that falls are prevalent among older breast cancer survivors. However, fall risk in this population has not been comprehensively examined. Therefore, we compared fall risk in older women post-breast cancer diagnosis...
Source: SafetyLit - Category: International Medicine & Public Health Tags: Age: Elder Adults Source Type: news
Conditions:   Advanced Solid Tumor;   Breast Neoplasms Interventions:   Drug: BPI-1178;   Drug: Fulvestrant;   Drug: Letrozole Sponsor:   Beta Pharma (Suzhou) Co., Ltd. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   HER2-positive Breast Cancer Intervention:   Diagnostic Test: TCHP Sponsor:   Fudan University Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Breast Cancer Interventions:   Procedure: Omission of axillary lymph node dissection;   Radiation: Omission of regional irradiation Sponsor:   Karolinska Institutet Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
AbstractBackgroundChemo ‐ and radiotherapy for breast cancer (BC) can lead to cardiotoxicity even years after the initial treatment. The pathophysiology behind these late cardiac effects is poorly understood. Therefore, we studied a large panel of biomarkers from different pathophysiological domains in long‐term BC sur vivors, and compared these to matched controls.Methods and resultsIn total 91 biomarkers were measured in 688 subjects: 342  BC survivors stratified either to treatment with chemotherapy ± radiotherapy (n = 170) or radiotherapy alone (n = 172) and matched controls. Mean age was 59 &t...
Source: European Journal of Heart Failure - Category: Cardiology Authors: Tags: Research Article Source Type: research
Ellie Graham, from Liverpool, discovered a pea-sized lump after experiencing shooting pains in her right side last summer. She was diagnosed with stage three breast cancer.
Source: the Mail online | Health - Category: Consumer Health News Source Type: news
Researchers from Tennessee have developed a navigation technique that employs...Read more on AuntMinnie.comRelated Reading: 3D micro-CT primed to revamp breast cancer imaging 3D printing may improve safety of upper GI surgery 3D-printed head customizes neurosurgery simulation How can 3D printing improve kidney cancer surgery? Portable gaming sensor enables 3D scans of elephantiasis
Source: AuntMinnie.com Headlines - Category: Radiology Source Type: news
(The Francis Crick Institute) Healthy lung cells support the survival of breast cancer cells, allowing them to hibernate in the lung before forming secondary tumors, according to new research, conducted in mice, from the Crick. The findings could help the development of new treatments that interfere with this behavior, reducing the number of secondary cancers.
Source: EurekAlert! - Biology - Category: Biology Source Type: news
(University of Waterloo) Researchers have developed a new, inexpensive technology that could save lives and money by routinely screening women for breast cancer without exposure to radiation. The system, developed by researchers at the University of Waterloo, uses harmless microwaves and artificial intelligence (AI) software to detect even small, early-stage tumors within minutes.
Source: EurekAlert! - Medicine and Health - Category: International Medicine & Public Health Source Type: news
We examined the pathogenic variant/likely pathogenic variant (PV/LPV) prevalence for 20 genes by clinical factors, demographics, and personal or family cancer history. We calculated adjusted odds ratios for the association between race/ethnicity and mutation results. The majority of women (65.4%) were referred post-breast or ovarian cancer diagnosis. The overall prevalence of any PV/LPV result was 11.7%. Overall, nearly 5.4% hadBRCA1/2 mutations, while 6.3% had at least one mutation in non-BRCA genes. In the subset with any PV/LPV result, 55.0% of the total mutations were in non-BRCA genes. The distribution of mutations wa...
Source: Journal of Community Genetics - Category: Genetics & Stem Cells Source Type: research
More News: Breast Cancer | Cancer | Cancer & Oncology | Epidemiology | Study